3,209 Shares in Becton, Dickinson and Company $BDX Purchased by Compass Wealth Management LLC

Compass Wealth Management LLC bought a new stake in Becton, Dickinson and Company (NYSE:BDX) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 3,209 shares of the medical instruments supplier’s stock, valued at approximately $486,000.

Several other large investors have also recently bought and sold shares of BDX. Imprint Wealth LLC bought a new stake in shares of Becton, Dickinson and Company during the 3rd quarter worth about $25,000. SHP Wealth Management bought a new position in shares of Becton, Dickinson and Company in the fourth quarter valued at approximately $26,000. Meeder Asset Management Inc. increased its stake in shares of Becton, Dickinson and Company by 152.2% during the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock valued at $27,000 after acquiring an additional 102 shares during the period. Main Street Group LTD acquired a new position in shares of Becton, Dickinson and Company during the first quarter valued at approximately $29,000. Finally, Bell Investment Advisors Inc bought a new stake in Becton, Dickinson and Company during the second quarter worth approximately $29,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Insider Transactions at Becton, Dickinson and Company

In other news, EVP Michael David Garrison sold 1,100 shares of the company’s stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total transaction of $160,226.00. Following the completion of the sale, the executive vice president directly owned 13,172 shares of the company’s stock, valued at $1,918,633.52. This represents a 7.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total value of $440,887.92. Following the completion of the transaction, the executive vice president owned 14,856 shares of the company’s stock, valued at $2,686,559.04. This trade represents a 14.10% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 11,779 shares of company stock valued at $1,974,669 over the last three months. Company insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Trading Down 0.5%

Shares of NYSE:BDX opened at $181.17 on Wednesday. The stock has a market capitalization of $49.92 billion, a price-to-earnings ratio of 54.57, a PEG ratio of 12.93 and a beta of 0.19. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $187.35. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87. The company has a 50 day moving average price of $159.06 and a 200 day moving average price of $161.12.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.14 by $0.09. The firm had revenue of $4.98 billion for the quarter, compared to analyst estimates of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The firm’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, research analysts anticipate that Becton, Dickinson and Company will post 12.67 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be issued a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date is Wednesday, September 9th. Becton, Dickinson and Company’s payout ratio is presently 126.51%.

Analyst Upgrades and Downgrades

BDX has been the subject of a number of research reports. Jefferies Financial Group reaffirmed a “buy” rating and set a $210.00 price target on shares of Becton, Dickinson and Company in a research note on Thursday, August 6th. Citigroup reissued a “buy” rating on shares of Becton, Dickinson and Company in a research note on Thursday, August 13th. Royal Bank Of Canada upped their price objective on Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a “sector perform” rating in a report on Thursday, August 13th. Piper Sandler raised their target price on Becton, Dickinson and Company from $161.00 to $175.00 and gave the company a “neutral” rating in a research note on Friday, August 7th. Finally, Stifel Nicolaus set a $195.00 target price on Becton, Dickinson and Company in a report on Friday, August 7th. Eight analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Becton, Dickinson and Company currently has a consensus rating of “Hold” and a consensus target price of $185.67.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.